Metformin prevents NGF-dependent proliferative and pro-angiogenic effects in epithelial ovarian cancer cells and endothelial cells

A2780		В	Ν	Μ	M+N	GW	Ab	GW+N	Ab+N
G0/G1	Mean	75.9	68.1	82.9	78.3 ^c	77.8 ^d	76.2 ^d	76.8 ^d	76.9 ^d
	SEM	1.4	3.5	2.2	3.5	2.0	1.6	1.7	1.4
S	Mean	11.8	16.7	5.5 ^a	9.8 ^c	11.4	12.3	12.0	13.5
	SEM	1.7	2.8	1.5	2.5	2.1	2.1	2.2	1.6
G2/M	Mean	12.3	15.2 ^a	11.6	11.9	10.8 ^d	11.5 ^c	11.2 ^c	9.6 ^d
	SEM	0.8	0.8	1.3	1.5	0.4	0.8	0.8	0.6

HOSE

G0/G1	Mean	82.1	79.1 ^a	86.1 ^a	86.1 ^d	82.1 ^c	82.3 ^c	82.6 ^c	84.9 ^c
	SEM	1.0	0.5	1.2	1.2	1.0	1.1	1.0	1.0
S	Mean	8.6	8.1	5.2 ^b	5.2 ^d	9.0	8.7	8.7	8.0
	SEM	0.6	0.1	0.4	0.3	0.7	0.7	0.7	0.7
G2/M	Mean	9.3	12.8 ^a	8.7	8.7 ^c	8.9 ^c	9.0	8.7 ^c	7.1 ^c
	SEM	0.9	0.5	0.9	0.9	0.7	1.1	0.5	0.4

EA.hy926

G0/G1 Mean 80.6	77.4 84.2	83.8 ^c 83.7 ^c	83.7 ^c	87.0 ^c	86.8 ^d
-----------------	-----------	-------------------------------------	-------------------	-------------------	-------------------

	SEM	1.6	1.2	2.7	2.4	2.4	2.0	1.2	1.3
S	Mean	11.6	13.6	10.6	9.9	10.1	9.8	8.1 ^c	7.9 ^c
	SEM	1.3	1.2	1.8	1.6	1.6	1.2	0.2	0.5
G2/M	Mean	7.8	9.0 ^a	5.2 ^a	6.3	6.2 ^d	6.5 ^c	4.9 ^d	5.3 ^d
	SEM	0.6	0.3	0.9	1.1	1.0	1.0	1.0	1.0

Table S1. Cell cycle stages of A2780, HOSE and EA.hy926 cells.

Cells were treated with metformin 10 mM (M) for 48 hours or NGF 100 ng/mL (N), TRKA inhibitor GW441756 (GW, 20 nM) or a NGF-neutralizing antibody (Ab, 5 μ g/mL) for 6 hours. The percentages of cells in different stages of the cell cycle were measured (N=4). Statistically significant changes are indicated as a= p<0.05 and b= p<0.01 respect to basal condition (B); c=p<0.05 and d= p<0.01 respect to NGF group.





Cells were stimulated with NGF (25, 50 and 100 ng/mL) for 48 hours and then cell viability was evaluated in A2780 (A), HOSE (B) and EA.hy926 (C) cells (N=3, triplicate). Statistically significant changes are indicated as *= p<0.05, **= P<0.01 and ***= P<0.001. Statistical analysis: Kruskal Wallis test.



Figure S2: Metformin decreases viability of A2780 and EA.hy926 cells.

Cells were stimulated with NGF (25, 50 and 100 ng/mL) for 48 hours and then viability was evaluated in A2780 (A), HOSE (B) and EA.hy926 (C) cells (N=3, triplicate). B: basal; M0.5: metformin 0.5 mM; M5: metformin 5 mM; N: NGF 100 ng/mL. Statistically significant changes are indicated as *= p<0.05, **= P<0.01 and ***= P<0.001. Statistical analysis: Kruskal Wallis test.



Figure S3: Metformin treatment precludes NGF-enhanced viability and numbers of A2780, HOSE and EA.hy926 cells.

A2780 cells (A,D,G,J), HOSE cells (B,E,H,K) and EA.hy926 cells (C,F,I,L) were treated with metformin (0.5 mM and 5 mM) and NGF (100 ng/mL) for 48 hours. (N=3, triplicate). B: basal; M0.5: metformin 0.5 mM; M5: metformin 5 mM; N: NGF 100 ng/mL. Statistically significant differences are indicated as *= p<0.05 **= p<0.01 and ***= p<0.001. Statistical analysis: Kruskal Wallis test.



Figure S4. Metformin treatment precludes NGF-enhanced A2780 cell numbers

Representative images of A2780 cells treated with metformina 10 mM (M) and NGF 100 ng/mL (N) for 48 hours are shown. Cells were counted after Acridine Orange & Propidium Iodide staining. B: basal condition. Green dots indicate live cells in each condition.



Figure S5: NGF and VEGF enhanced the angiogenic score of EA.hy926 cells.

Cells seeded in fresh medium were stimulated with NGF (100 ng/mL) or the positive control VEGF (20 ng/mL) and then incubated on matrigel-covered plates for 8 hours. A: Representative images after analysis by Image J Angiogenesis Analyzer, which highlight cell rows as blue dots and where light blue circles correspond to junctions (B), polygonal structures or meshes (C) respectively. D: Angiogenic score of EA.hy926 cells. (8 images per group; N=3 for VEGF group and N=4 for rest of groups). Statistically significant

differences are indicated as *= p<0.05; **= p<0.01 ****= p<0.0001, according to Kruskal Wallis test. Magnification bar = 50 μ m.